Manchester, United Kingdom — June 26, 2026 — The 106th Annual Meeting of the British Association of Dermatologists (BAD), scheduled for 2026 in Manchester, United Kingdom, is projected to attract approximately 1800 delegates from across the globe. This significant gathering, set to open on June 30, 2026, underscores the association's commitment to advancing dermatology through education and research.
Educational and Research Mandate
The British Association of Dermatologists (BAD) functions as a professional membership body for dermatologists in the UK and operates as a charity dedicated to medical education, research, and professional practice and standards. The mission of the British Association of Dermatologists is to champion Dermatology in the UK for the public benefit. This encompasses developing educational content and courses, facilitating and publishing dermatology research, running dermatology registries, and promoting innovation in dermatology care.
The event's Exhibition Overview highlights three full days of educational content covering all aspects of dermatology. This focus is critical for ensuring that clinical practice remains aligned with the latest scientific understanding and for addressing the evolving needs of patients and regulatory bodies.
Program Structure and Target Audience
The Annual Meeting is structured to provide a comprehensive educational experience for its target audience, which includes dermatologists in the UK and delegates from across the world. The program will feature plenary sessions with keynote lecturers, offering insights into current and future directions in dermatological science and practice. Concurrent specialist sessions, organized by Special Interest Groups, will delve into specific areas of research and clinical application.
Further educational opportunities will be provided through Hot Topic talks and pre-conference sessions. The inclusion of an accompanying social programme aims to facilitate networking among researchers and clinicians, fostering collaborations that can drive future advancements in the field. This structure supports the BAD's objective of engaging with decision-makers and stakeholders within the dermatology community and wider health system.
Industry Engagement and Core Exhibits
A central component of the event, as outlined in the Core Exhibit Sectors, is a large pharmaceutical exhibition. This exhibition serves as a platform for industry partners to present new therapeutic agents and diagnostic tools relevant to dermatology. The presence of such an exhibition is pertinent for researchers and clinicians seeking to understand the pipeline of new treatments and their potential impact on patient outcomes and clinical guidelines.
The Scale Data confirms the event's reach, with the 106th Annual Meeting (2026) attracting around 1800 delegates. This scale ensures a broad representation of perspectives from both academic and clinical settings, fostering a robust exchange of knowledge.
For further details and registration, interested parties may visit the official website at https://badannualmeeting.co.uk.